
    
      Eligible participants will receive single doses of HEPLISAV-BÂ® at Weeks 0, 4, 8, and 16 and
      will be followed through Week 68 or end of study (EOS). The study is designed to evaluate the
      immunogenicity over a 20-week period and safety over a 68-week period.
    
  